Opening: Patient Misconceptions
IVF is Neither the "Last Resort" Nor a "Magic Bullet"
In outpatient clinics, we often encounter two types of patients: those who view IVF as a "last resort," trying every folk remedy, herbal medicine, tubal hydrotubation, and timed intercourse after ovulation induction for two or three years before consulting about IVF. The other type is the opposite—they see IVF as a "shortcut," believing that once they do it, they will succeed immediately, and even demand to go straight to third-generation IVF. Both mindsets need adjustment.
IVF (In Vitro Fertilization-Embryo Transfer, IVF-ET) is an assisted reproductive technology with clear medical indications. It addresses fertility barriers at specific stages, not a universal solution for all infertility problems. Whether it is suitable, when to do it, and how to do it depend on multiple factors, including the specific cause, ovarian reserve, age, and uterine conditions. The following clarifies the most common questions from a clinical perspective.
What is IVF? What are the Differences Between First, Second, and Third Generation?
The full name of IVF is "In Vitro Fertilization-Embryo Transfer." The core steps are: retrieving eggs from the woman's ovaries, combining them with sperm in a laboratory to form embryos, and then transferring the embryo back into the uterus for implantation and development. The entire process bypasses the natural fertilization step in the fallopian tubes.
| Technology Type | Indications | Key Difference |
|---|---|---|
| First Generation IVF | Tubal blockage, ovulation disorders, endometriosis, unexplained infertility | Eggs and sperm combine naturally in a culture dish; no intervention in the fertilization process |
| Second Generation ICSI | Male factor: low sperm count, poor motility, high abnormal morphology, or previous IVF fertilization failure | A single sperm is selected under a microscope and injected directly into the egg to overcome fertilization障碍 |
| Third Generation PGT | One partner has a chromosomal structural abnormality, a single-gene genetic disorder, recurrent miscarriage, or recurrent implantation failure | Genetic testing is performed on embryos before transfer to select those with normal chromosomes or without the disease-causing gene |
Choosing which technology is not about "the more advanced, the better," but rather based on specific medical indications. Insisting on third-generation IVF without a genetic indication not only increases costs but may also potentially impact the embryo due to the biopsy procedure. The doctor will provide recommendations based on the cause of infertility and test results.
When is IVF Necessary?
The indications for IVF are clearly defined in the National Health Commission's "Technical Specifications for Human Assisted Reproductive Technology." It is important to emphasize that not all infertility requires IVF; some cases can be resolved with ovulation induction drugs, hysteroscopic surgery, or intrauterine insemination. The following situations are generally recommended to proceed directly to an IVF cycle:
- Tubal Factor: Bilateral tubal blockage, severe adhesions, or hydrosalpinx that cannot be surgically repaired or remains blocked after repair.
- Male Factor: Severe oligospermia (sperm concentration < 5×10⁶/mL), asthenospermia (progressive motility < 10%), or azoospermia (sperm retrievable via testicular biopsy).
- Ovulation Disorders: Polycystic ovary syndrome (PCOS) with no pregnancy after more than 6 cycles of ovulation induction, or advanced age with diminished ovarian reserve.
- Endometriosis: Moderate to severe endometriosis, or mild endometriosis with no pregnancy after surgery and ovulation induction.
- Unexplained Infertility: No abnormalities found in either partner, but no pregnancy after more than 1 year of regular attempts (6 months if the woman is ≥35 years old), and failure with other fertility treatments.
- Immune Infertility: Positive anti-sperm antibodies or other immune factors causing fertilization障碍.
When is it not suitable to start IVF immediately: Uncontrolled thyroid dysfunction, uncorrected hyperprolactinemia, untreated intrauterine adhesions, endometrial polyps or fibroids affecting the uterine cavity, acute pelvic infection, or severe systemic diseases (e.g., uncontrolled hypertension, diabetes).
In these cases, the underlying condition should be treated first before assessing the timing for IVF.
How Do Doctors Evaluate IVF Indications and Success Rates?
The reproductive specialist's decision-making logic is: first, identify the core cause of infertility; second, assess whether IVF can effectively address that cause; and third, determine if the patient's physical condition can safely support a pregnancy. The specific evaluation pathway is as follows:
- Female Ovarian Reserve Assessment: On day 2-3 of the menstrual cycle, check serum AMH, FSH, LH, and E2, along with an antral follicle count. AMH is currently the most stable indicator of ovarian reserve. AMH < 1.0 ng/mL indicates diminished reserve, and < 0.5 ng/mL indicates severely diminished reserve.
- Male Semen Analysis: At least 2 semen analyses, focusing on sperm concentration, progressive motility, and normal morphology rate.
- Uterine Environment Assessment: Transvaginal ultrasound to rule out uterine cavity masses; hysteroscopy or endometrial biopsy if necessary.
- General Health Status: Thyroid function, glucose metabolism, coagulation function, and infectious disease screening (Hepatitis B, Hepatitis C, Syphilis, HIV).
The doctor will comprehensively analyze these data to estimate the "expected number of eggs," "expected number of embryos," and "probability of pregnancy per single transfer," and then discuss with the patient whether to start and which protocol to choose. If ovarian reserve is extremely low, no sperm can be obtained from azoospermia, or the uterine condition is unsuitable for pregnancy, the doctor will clearly advise against it or recommend adjusting the plan.
Interpretation of Key Examination Indicators: AMH, FSH, Antral Follicle Count, and Semen Analysis
These indicators are the core basis for judging the feasibility and expected outcomes of IVF, and they are also the most common source of confusion for patients.
AMH (Anti-Müllerian Hormone)
Secreted by the granulosa cells of preantral and small antral follicles in the ovaries, AMH represents the number of remaining follicles in the ovaries. AMH levels decline with age and are not affected by the menstrual cycle, so they can be tested at any time.
Clinical reference: AMH > 2.0 ng/mL is normal; 1.0–2.0 ng/mL indicates mild decline; 0.5–1.0 ng/mL indicates moderate decline; < 0.5 ng/mL indicates severe decline. Low AMH does not mean IVF is impossible, but the number of retrievable eggs will be reduced, requiring adjustments to the stimulation protocol and management of expectations.
FSH (Follicle-Stimulating Hormone)
Measured on day 2-3 of the menstrual cycle, FSH reflects the pituitary's drive to the ovaries. FSH < 8 IU/L suggests normal ovarian reserve; 8–12 IU/L is borderline; > 12 IU/L suggests diminished reserve. Elevated FSH is often accompanied by low AMH, but FSH fluctuates more between cycles and is less stable than AMH.
Antral Follicle Count (AFC)
Performed via transvaginal ultrasound in the early menstrual phase, counting the number of follicles measuring 2–10 mm in both ovaries. An AFC of 5–10 is normal; fewer than 5 suggests reduced reserve. Combining AFC with AMH provides a more accurate prediction of ovarian response to stimulation drugs.
Core Parameters of Semen Analysis
| Parameter | WHO 5th Edition Lower Reference Limit | Clinical Significance |
|---|---|---|
| Sperm Concentration | 15×10⁶ /mL | Below this indicates oligospermia, possibly requiring ICSI |
| Progressive Motility | 32% | Below this indicates asthenospermia, reduced fertilizing ability |
| Normal Morphology | 4% | Below this indicates teratozoospermia, may affect fertilization |
The Impact of Age on IVF: Key Differences Across Age Groups
Age is one of the most important factors affecting IVF outcomes. The core reason is that oocyte quality declines with age, impacting fertilization rates, embryo developmental potential, and chromosomal normality.
| Age Group | Ovarian Reserve Characteristics | Clinical Pregnancy Rate per Transfer Cycle (Reference Range) | Key Strategy |
|---|---|---|---|
| ≤ 34 years | Normal or good reserve, good egg quality | 50%–65% | Conventional stimulation protocol, single embryo transfer to reduce multiple pregnancy risk |
| 35–37 years | Reserve begins to decline, risk of chromosomal abnormalities increases | 40%–50% | Advise starting the cycle as soon as possible; consider PGT-A screening |
| 38–40 years | Reserve significantly reduced, egg quality declines faster | 25%–40% | Need more aggressive stimulation protocol; may require embryo accumulation |
| 41–42 years | Reserve severely diminished, rate of normal embryos significantly lower | 15%–25% | Strictly evaluate follicle count; consider possibility of egg donation |
| ≥ 43 years | Extremely low reserve, difficult to retrieve eggs, very high rate of chromosomal abnormalities in embryos | < 10% | Full communication of expectations; most centers recommend considering egg donation |
The above data are statistical ranges from large domestic reproductive centers, with significant individual variation. For women over 40, it is recommended to undergo chromosomal screening (both partners) and uterine cavity assessment before starting IVF to improve the efficiency of a single cycle.
Easily Overlooked Details: Preoperative Examinations, Endocrine Status, and Male Factors
During the IVF preparation phase, the following details are often overlooked but can directly affect cycle progress or outcomes.
- Validity of Test Results: Infectious disease screenings (Hepatitis B, Hepatitis C, Syphilis, HIV) are valid for 6 months; chromosomal karyotyping is valid for life; semen analysis should be repeated within 3 months. Tests beyond their validity period must be redone; otherwise, the medical record cannot be established.
- Vitamin D Levels: Vitamin D deficiency is associated with diminished ovarian reserve and reduced endometrial receptivity. It is recommended to test 25-hydroxyvitamin D before starting the cycle and supplement to normal levels if below 30 ng/mL.
- Thyroid Function: TSH above 2.5 mIU/L may affect embryo implantation and early development. It is recommended to adjust TSH to below 2.5 before starting the cycle.
- Male Examination is Equally Important: Some men believe "I'm healthy, so there's no problem," but semen quality is not directly related to physical fitness. Men need at least 2 semen analyses, chromosomal karyotyping, and Y-chromosome microdeletion testing (in cases of azoospermia).
- Psychological State: Persistent anxiety and insufficient sleep can affect the endocrine axis, potentially indirectly impacting follicle development and endometrial receptivity. Regular sleep and moderate exercise are recommended before starting the cycle.
Common Pitfalls in Decision-Making: Blindly Choosing Technology and Ignoring Underlying Causes
From clinical observation, the following four misconceptions are most common:
- Blindly Pursuing Third-Generation IVF: Insisting on PGT without a genetic indication not only increases costs (approximately 20,000–40,000 RMB) but also causes some embryo loss due to the biopsy procedure, which may be counterproductive for patients with few embryos.
- Ignoring Basic Cause Investigation: Proceeding directly to transfer without a hysteroscopy, only to discover endometrial polyps or chronic endometritis after repeated implantation failure. It is recommended to complete a uterine cavity assessment before the first transfer, especially for those with a history of miscarriage or uterine procedures.
- Excessive "Tiao Li" (Regimen) Delaying the Window of Opportunity: Some patients, due to low AMH, spend six months to a year on herbal medicine, acupuncture, and supplements, only to see their AMH drop further. For patients with clear IVF indications and advanced age, it is recommended to start the cycle within 3 months; regimen adjustments can be done concurrently, not as a substitute.
- Choosing Unregulated Institutions: Some institutions use slogans like "Guaranteed Success" or "Full Refund if Not Successful," but lack legal qualifications. To determine if an institution is legitimate, check whether it holds the "Approval Certificate for Human Assisted Reproductive Technology" and whether it is on the list published by the National Health Commission.
Analysis and Coping Strategies for Different Scenarios
The following three representative scenarios from outpatient clinics help illustrate the individualized logic of IVF decision-making.
Scenario 1: 32 years old, bilateral tubal blockage, AMH 3.2 ng/mL, normal male semen.
Core advantages: good age and ovarian reserve. Suitable for first-generation IVF. Expected to retrieve 10–15 eggs, with 5–8 usable embryos. Probability of pregnancy per single transfer is approximately 55%–65%. Recommended: single embryo transfer, freeze remaining embryos. PGT is not needed.
Scenario 2: 39 years old, AMH 0.8 ng/mL, mild male asthenospermia, no pregnancy after 2 years of trying.
Diminished ovarian reserve requires starting the cycle as soon as possible. Options: mild stimulation or antagonist protocol, retrieving 2–5 eggs per cycle. May need to accumulate embryos over 2–3 cycles. Recommended: culture embryos to blastocyst stage and perform PGT-A screening to improve efficiency per transfer. The male partner should undergo semen optimization simultaneously.
Scenario 3: 42 years old, AMH 0.3 ng/mL, FSH 15 IU/L, previously had one egg retrieval at another hospital with no eggs obtained.
Extremely low ovarian reserve; conventional stimulation has a low probability of retrieving eggs. Options: try a natural cycle or very low-dose stimulation; probability of making an embryo is low. Simultaneously consider egg donation as a backup plan. In-depth communication with the doctor about expectations is necessary to avoid financial and psychological depletion from repeated failure.
Common Questions About the Process, Cost, and Time
Based on daily records from practitioners, the following questions are most frequently asked:
- How long does it take from examination to transfer? Female preoperative examinations take about 1 month (including long-cycle items like chromosomes). After filing, ovarian stimulation takes about 10–14 days. After egg retrieval, embryo culture takes 3–6 days. Fresh embryos can be transferred in the same cycle, or frozen embryos can be transferred later. A single complete cycle takes about 2–3 months.
- What is the approximate cost? At a legitimate domestic reproductive center, a conventional IVF cycle costs approximately 30,000–50,000 RMB (excluding medication cost variations). ICSI adds about 5,000–8,000 RMB, and PGT adds about 20,000–40,000 RMB. Total cost varies depending on the dosage and brand of stimulation drugs, and whether frozen embryo transfer is used.
- How much time off work is needed? During the stimulation phase, frequent hospital visits for follicle monitoring are required (about 5–8 times), each taking half a day. The egg retrieval day requires 1 day of rest. After transfer, 2–3 days of rest are recommended. Overall, the impact on work is limited, but time needs to be coordinated in advance.
- What should be noted after transfer? Normal activity is allowed; avoid strenuous exercise and prolonged standing. Absolute bed rest is not required; prolonged bed rest actually increases the risk of thrombosis. Use luteal support medication as prescribed by the doctor; do not stop on your own.
Risk Reminder
IVF is not a zero-risk medical procedure. Ovarian hyperstimulation syndrome (OHSS) may occur during stimulation, presenting with bloating, nausea, and decreased urine output; severe cases require hospitalization. Egg retrieval surgery carries risks of bleeding, infection, and injury to adjacent organs, with an incidence of about 0.1%–0.5%. Multiple pregnancies increase the risk of preterm birth, gestational hypertension, diabetes, and other perinatal complications. Single embryo transfer is recommended, especially for young women with good uterine conditions.
All treatment decisions should be made after evaluation by a qualified reproductive specialist at a legitimate reproductive center. It is not recommended to determine a treatment plan directly through online "consultations" or to start a cycle blindly without completing basic examinations. Assisted reproduction is a medical act, not a consumer transaction.
This article is compiled based on clinical consensus in assisted reproductive medicine and is not a substitute for individual diagnosis and treatment. Please consult a doctor at a legitimate reproductive center for specific treatment plans.
Comments (0)